0.9024

2.22% -0.0205

After Hours: .9085 0.0061 +0.68%

Bionomics Ltd. ADR (BNOX)

Overview News Price History Discussions Forecast

Bionomics Ltd. ADR stock is currently priced at $0.9024, with a 24-hour trading volume of 32,105. It has seen a -2.22% decreased in the last 24 hours and a -5.91% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.9208 pivot point. If it approaches the $0.8963 support level, significant changes may occur.

Previous Close:

$0.9229

Open:

$0.9

24h Volume:

32,105

Market Cap:

$9.65M

Revenue:

Net Income/Loss:

P/E Ratio:

-0.2772

EPS:

-3.2558

Net Cash Flow:

1W Performance:

-5.12%

1M Performance:

-5.91%

6M Performance:

-53.48%

1Y Performance:

-67.21%

1D Range:

$0.90

$0.9301

52W Range:

$0.84

$6.41

Bionomics Ltd. ADR Stock (BNOX) Company Profile

Name

Bionomics Ltd. ADR

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

61 8 8150 7400

Address

200 Greenhill Road, Eastwood

Employee

Twitter

Next Earnings Date

2024-05-17

Latest SEC Filings

BNOX's Discussions on Twitter

Bionomics Ltd. ADR Stock (BNOX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-10-22	Initiated	Berenberg	Buy
Jan-10-22	Initiated	Cantor Fitzgerald	Overweight
Jan-10-22	Initiated	Evercore ISI	Outperform
Jan-10-22	Initiated	H.C. Wainwright	Buy

Bionomics Ltd. ADR Stock (BNOX) Latest News

Bears are Losing Control Over Bionomics Limited Unsponsored ADR (BNOX), Here's Why It's a 'Buy' Now - Yahoo Singapore News

Yahoo Singapore News

Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder

GlobeNewswire Inc.

Bionomics reports promising PTSD treatment trial results By Investing.com - Investing.com

Investing.com

Bionomics Ltd. ADR Stock (BNOX) Financials Data

There is no financial data for Bionomics Ltd. ADR (BNOX). Check out other stocks for more information.

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.